Nuvectis Pharma (NVCT) Preferred Stock Liabilities (2021)

Nuvectis Pharma has disclosed Preferred Stock Liabilities across 1 years of filings, most recently posting $15.2 million for Q4 2021.

• Preferred Stock Liabilities for Q4 2021 came in at $15.2 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2021 was $15.2 million (changed N/A YoY), and the FY2021 annual result was $15.2 million, changed N/A from the prior year.
• Preferred Stock Liabilities came in at $15.2 million for Q4 2021 at Nuvectis Pharma, roughly flat from $15.2 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $15.2 million in Q3 2021 to a low of $11.2 million in Q2 2021.